Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.78 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17273858 | 1.00 | KMT2A (0.78) | KMT2AHTTLMNANPC1RAB9A | |
| SCHEMBL4803949 | 1.00 | KMT2A (0.78) | KMT2AHTTLMNANPC1RAB9A | |
| SCHEMBL965286 | 0.98 | KMT2A (0.82) | KMT2AHTTLMNANPC1RAB9A | |
| SCHEMBL19741751 | 0.93 | — | — | |
| SCHEMBL20676624 | 0.86 | KMT2A (0.59) | KMT2AHTTLMNANPC1RAB9A | |
| Alanine SCHEMBL27722582 | 0.86 | KMT2A (0.58) | KMT2AHTTLMNANPC1RAB9A | |
| Alanine SCHEMBL28772932 | 0.83 | KMT2A (0.60) | KMT2AHTTLMNANPC1RAB9A | |
| SCHEMBL1651682 | 0.83 | LMNA (0.61) | KMT2AHTTLMNANPC1RAB9A | |
| SCHEMBL2888303 | 0.82 | KMT2A (0.64) | KMT2AHTTLMNA | |
| Tert-Butyl Formate SCHEMBL28832508 | 0.82 | KMT2A (0.53) | KMT2AHTTLMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4511373-A1 | PI3K? INHIBITORS | Synnovation Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | claimed |
| CN-114585619-B | Alpha-D-galactopyranoside derivatives | 爱杜西亚药品有限公司 | 2024-09-27 | — | — | CN | claimed |
| WO-2023205680-A1 | PI3Kα INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | claimed |
| EP-4021904-A1 | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2022-07-06 | — | — | EP | claimed |
| CN-114585619-A | alpha-D-galactopyranoside derivatives | 爱杜西亚药品有限公司 | 2022-06-03 | — | — | CN | claimed |
| EP-3027604-A2 | NOVEL QUINAZOLINONES AS BROMODOMAIN INHIBITORS | Zenith Epigenetics Corp. (CA) | 2016-06-08 | — | — | EP | claimed |
| US-20250257056-A1 | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-08-14 | — | — | US | disclosed |
| US-12319672-B2 | Alpha-D-galactopyranoside derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-06-03 | — | — | US | disclosed |
| EP-4511373-A1 | PI3K? INHIBITORS | Synnovation Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| CN-114585619-B | Alpha-D-galactopyranoside derivatives | 爱杜西亚药品有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-11873288-B2 | Inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-16 | — | — | US | disclosed |
| CN-111655681-B | Heterocyclylamino-substituted triazoles as modulators of Rho-related protein kinases | 莱德克斯制药公共有限公司 | 2024-01-05 | — | — | CN | disclosed |
| WO-2023205680-A1 | PI3Kα INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-1192135-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001096305-A1 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2001-12-20 | — | — | WO | disclosed |
| WO-2001044226-A1 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2001-06-21 | — | — | WO | disclosed |
| WO-2000076970-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
| US-4560692-A | ANTICONVULSANTS OR ANXIOLYTIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1985-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257056-A1 | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | LGALS1, LGALS3, LGALS2 | KMT2A 4539/4885HTT 2509/4885LMNA 964/4885 |
| US-11873288-B2 | Inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) | FAAH, FAAH2, EPHX2 | KMT2A 1309/4885HTT 4389/4885LMNA 4459/4885 |
| US-12319672-B2 | Alpha-D-galactopyranoside derivatives | LGALS1, LGALS3, LGALS2 | KMT2A 4533/4885HTT 3410/4885LMNA 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.